Head to Head Comparison: Anika Therapeutics (NASDAQ:ANIK) vs. BioNTech (NASDAQ:BNTX)

Anika Therapeutics (NASDAQ:ANIK) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Profitability

This table compares Anika Therapeutics and BioNTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-1.43%	1.87%	1.39%
BioNTech	-61.39%	-4.51%	-3.96%

Analyst Recommendations

This is a summary of recent ratings and target prices for Anika Therapeutics and BioNTech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1	1	2	0	2.25
BioNTech	1	5	12	1	2.68

Anika Therapeutics presently has a consensus target price of $22.00, suggesting a potential upside of 57.71%. BioNTech has a consensus target price of $122.27, suggesting a potential upside of 39.49%. Given Anika Therapeutics’ higher probable upside, analysts plainly believe Anika Therapeutics is more favorable than BioNTech.

Institutional and Insider Ownership

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Anika Therapeutics and BioNTech”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82 million	1.66	-$10.88 million	($0.13)	-107.31
BioNTech	$2.42 billion	9.16	-$1.29 billion	($6.85)	-12.80

Anika Therapeutics has higher earnings, but lower revenue than BioNTech. Anika Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Anika Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500.

Summary

BioNTech beats Anika Therapeutics on 8 of the 15 factors compared between the two stocks.

About Anika Therapeutics

Anika Therapeutics is a medical technology company focused on orthopedic care and regenerative medicine. Founded in 1992 and headquartered in Bedford, Massachusetts, the company develops products using hyaluronic acid, a substance found naturally in the body and used in treatments for joint and tissue conditions. Its products include Orthovisc and Monovisc, injectable hyaluronic acid treatments for knee osteoarthritis. Anika also offers orthopedic products for areas such as sports medicine, joint preservation, and bone repair, including its Tactoset bone-void filler.

About BioNTech

BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases. The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio. BioNTech works with partners to develop and distribute products internationally.